Kennedy offers FDA tobacco bill
This article was originally published in The Tan Sheet
Executive Summary
Senate Health, Education, Labor and Pensions Committee Chairman Edward Kennedy, D-Mass., introduces the Family Smoking Prevention and Tobacco Control Act, S. 982. The bill, offered May 5, is a virtual copy of legislation the House passed to give FDA authority over tobacco products, with only minor technical changes, according to a staffer for the House Energy and Commerce Committee. H.R. 1256, introduced by Energy and Commerce Chairman Rep. Henry Waxman, D-Calif., passed the House in April. Waxman expressed hope that the Senate would pass the legislation after the spring recess, but a staffer for Senate Majority Leader Harry Reid, D-Nev., said the bill is unlikely to reach the Senate floor until after Memorial Day (1"The Tan Sheet" April 20, 2009, In Brief)
You may also be interested in...
Waxman emphasizes children in tobacco oversight
House Energy and Commerce Committee Chairman Henry Waxman says his legislation to give FDA regulatory authority over tobacco would help meet the "biggest challenge" to reducing smoking - preventing children from starting to use tobacco. In a Minnesota Public Radio interview April 8, the California Democrat said he authored the Family Smoking Prevention and Tobacco Control Act, H.R. 1256, which passed the House April 2, in part to "stop cigarette companies from using flavors that would appeal to kids whether they be chocolate flavors or grape flavors or something sweet." Such formulations make the products appear "childlike" and "without any threat to health," he added (1"The Tan Sheet" April 6, 2009, p. 6). The Congressional Budget Office says in an April 13 cost estimate that implementing the bill will cost $10 million between 2010 and 2014, but the requirements will save $20 million between 2010 and 2019. Waxman said he expects the Senate has enough votes to stop a proposed filibuster and will pass the bill after Congress returns from the spring recess April 20 (2"The Tan Sheet" March 23, 2009, p. 12)
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.